Collection of Circulating Biomarkers in Pancreatic Cancer

NCT05743049 | Recruiting DMC

• 2 other identifiers: UPCC 20222852628
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.

Conditions

Pancreas Cancer

Outcome Measures

Primary Outcomes (1)

• To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.

  Through study completion, an average of 1 year

Secondary Outcomes (2)

• To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response.

  Through study completion, an average of 1 year

• To integrate the data and specimens to permit the most informative clinical-biologic research platform.

  Through study completion, an average of 1 year

Study Arms (1)

Blood specimens

Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma.

Other: Obtaining blood for analysis of various circulating biomarkers

Interventions

Obtaining blood for analysis of various circulating biomarkers OTHER

4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period

Blood specimens

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

known or suspected diagnosis of pancreatic adenocarcinoma

You may qualify if:

• The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
• The subject must be a patient of the University of Pennsylvania
• The subject must be able to provide informed consent
• The subject must be 18 years of age or older

You may not qualify if:

• Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead

Study Sites (1)

Abramson Cancer Center at University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Study Officials

• Mark O'Hara, MD

  Abramson Cancer Center, University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Liudmila Mazaleuskaya, PhD

CONTACT

267-455-9141; mazali@pennmedicine.upenn.edu

Mark O'Hara, MD

CONTACT

215-360-0919; Mark.OHara@pennmedicine.upenn.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2023
• First Posted: February 24, 2023
• Study Start: February 27, 2023
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): January 15, 2028
• Last Updated: March 10, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)